HCW Biologics Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by HCW Biologics Inc. on June 14, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol HCWB.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on two proposals at the Annual Meeting:
- Proposal 1: Election of Director - Stockholders approved the election of Hing C. Wong as a Class III director for a three-year term expiring at the 2027 Annual Meeting.
- For: 24,165,521
- Withheld: 1,348,261
- Broker Non-Votes: 2,313,942
- Proposal 2: Ratification of Auditors - Stockholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
- For: 27,788,079
- Against: 7,646
- Abstain: 31,999
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard disclosure of the voting results.
Key Facts for Investor Verification
- Hing C. Wong was re-elected as a director for a term ending in 2027.
- Grant Thornton LLP was ratified as the independent auditor for the 2024 fiscal year.
- The company is classified as an emerging growth company.
- No financial performance metrics were disclosed in this specific filing.